Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951954 | 0.84 | PDE4D (0.50) | SIRT2SIRT1SIRT3PDE4DPKN1 | |
| SCHEMBL13849264 | 0.77 | FLT3 (0.42) | CHEK1 | |
| SCHEMBL4101339 | 0.74 | DGAT1 (0.47) | SIRT2SIRT1SIRT3PDE4DPKN1 | |
| SCHEMBL13849253 | 0.74 | HTR3A (0.39) | ALDH1A1KMT2A | |
| SCHEMBL12108636 | 0.73 | PKN1 (0.45) | SIRT2SIRT1SIRT3PDE4DPKN1 | |
| SCHEMBL1299865 | 0.72 | PKN1 (0.49) | SIRT2SIRT1SIRT3PDE4DPKN1 | |
| SCHEMBL13850423 | 0.72 | AURKA (0.48) | RHEBNPC1RAB9AKMT2AAURKA | |
| SCHEMBL1300899 | 0.71 | RAB9A (0.49) | SIRT2SIRT1SIRT3PKN1PKN2 | |
| SCHEMBL4089768 | 0.68 | HPSE (0.47) | KDM4EMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL4097487 | 0.67 | CHEK1 (0.51) | FGFR1KDRKDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | SIRT2 850/4885SIRT1 719/4885SIRT3 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.